International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1362-1368), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Overview of Fragile X Syndrome, Causes and Impact on Quality of Life

[1]Alshebana, Noora Abdulaziz H, [2]Alrowaithi, Bassmah Hassan M,
[3]Alrowathi, Khlood Ibraheem H, [4]Alghamdi, Rahaf Abdullah R,
[5]Alghamdi, Afnan Ali S

Abstract: **Present study was conducted to determine the etiological factors which contribute in the pathogenesis of Fragile X syndrome (FXS), which is mostly genetics factors, and to evaluate the quality of life among those FXS patients. We conducted this review paper by performing a search strategy among medical databases such MIDLINE, science-direct, from the instance time to 2016, including only studies published in English language and with human subjects only. Studies that demonstrate the genetics factors as a cause of FXS were included, in addition to those discussing the impact of FXS on quality of life on patients and their families. Fragile X syndrome (FXS) is the most frequent type of acquired intellectual special needs and is likewise linked to other neurologic and psychiatric conditions. While the molecular functions of FMRP are still being marked, FMRP is mainly developed to function in regulating mRNA metabolic process in brain. The wide variety of putative mRNA targets and several FMRP-interacting proteins with overlapping function might describe the large and variable physical phenotypes observed in FXS. FXS care needs substantial resources that are primarily non-medical in nature and are higher for children than for adults. Compared with associated diseases, FXS makes up an especially high problem for caretakers.**

Keywords: **Fragile X syndrome (FXS), medical databases, MIDLINE, FMRP, children than for adults.**

1. INTRODUCTION

Fragile X syndrome (FXS) is the most typical acquired form of intellectual disability (ID) [(1)]. which was described for the first time in 1943 by Martin and Bell [(2)]. It arises from an expansion mutation of a CGG repeat sequence in the very first exon of the FMR1 gene, resulting in transcriptional silencing of the gene and absence or considerable decrease of the gene product, delicate X mental retardation protein [(3,4)]. This protein is important for proper synaptic plasticity, neuronal morphology, and cognitive advancement, and its lack leads to differing levels of ID [(5)].

Patients impacted with FXS have more than 200 repeats of the CGG trinucleotide. On the other hand, premutation providers (55 to 200 repeats) although are not affected with the traditional FXS phenotype, can have other medical, psychiatric and neurological issues. In the last 15 years several advances have actually been made in the description of hereditary characteristics, function of the protein encoded by the FMR1 gene (FMRP), medicinal management and the description, in carriers of the premutation, of the Fragile X associated Tremor/Ataxia Syndrome (FXTAS) and vulnerable X-associated primary ovarian insufficiency (FXPOI) [(6,7)].

The real worldwide occurrence, identified by molecular assays, it's approximated in one per 5,000 men and in one per 4,000 to 6,000 females [(8)]. A variety of medical conditions and syndromes, related to carriers of the premutation including depression, anxiety, migraine headaches, high blood pressure, sleep apnea, immune mediated diseases including hypothyroidism and fibromyalgia, and FXTAS and FXPOI have actually been explained in the past 10 years [(9)]. The occurrence of the premutation in the general population is 1:130 -200 females and 1:250 to 450 males [(10)]. Tremor/Ataxia Syndrome takes place in around 40% of guys with the premutation and 16% of ladies, whereas FXPOI happens in approximately 16 to 20% of ladies with the premutation [(9)].

The associated burden appears to be significant. Patients display problems of discovering skills and behavioural problems that have a significant impact on independence throughout adult life, with only 10% of male FXS patients living individually [(11)]. A high share of the problem is attributable to co-occurring mental conditions: affect issues, including anxiety and depression, have been found to occur in one-half to more than two-thirds of FXS patients. More severe, self-injurious behaviour and aggressiveness are discovered in more than 50% of children and teenagers with FXS [(11)]. Likewise, the problem of FXS is considerable for the caregivers. In a current US research study of FXS patients, approximately one-third of the caregivers had seen an expert for anxiety, tension or depression throughout the previous year, and one-quarter took medication to deal with these symptoms [(12)]. Caretaker concern was extremely related to issue habits, and nearly one-third of the caretakers had actually been hurt by their child with FXS at least as soon as in the past year. Care of FXS patients involves regular contact with the medical and social care system, and subsequently, 79% of families reported a financial burden [(12)].

Objectives:

Present study was conducted to determine the etiological factors which contribute in the pathogenesis of Fragile X syndrome (FXS), which is mostly genetics factors, and to evaluate the quality of life among those FXS patients.

2. METHODOLOGY

We conducted this review paper by performing a search strategy among medical databases such MIDLINE, science-direct, from the instance time to 2016, including only studies published in English language and with human subjects only. studies that demonstrate the genetics factors as a cause of FXS were included, in addition to those discussing the impact of FXS on quality of life on patients and their families.

3. RESULTS

- ***Roles of Genetics in fragile X syndrome (FXS):***

FMR1 gene is identified by the presence of a polymorphic CGG triplet sequence in the 5 ′ UTR [(13,14)]. Expansion in this triplet sequence generates FXS, which is the prototype of unstable triplet growth conditions. The triplet irregularity specifies 4 types of alleles (**Figure 1**). Regular alleles have a number of CGG repeats, ranging from 5 to 54, with a mode of 30. Premutation (PM) alleles have a variety of CGG repeats, varying from 55 to 200. The Fragile X Syndrome is caused by an alteration in the FMR1 gene, with locus Xq27.3. This gene harbors a CGG repeat within the 5' Untranslated Region. Depending on the number of repeatings, 4 kinds of alleles are defined with various clinical manifestations [(6)]. Regular alleles, as much as 44 CGG repeats; premutation (PM) alleles, in between 55 and 200 and full anomaly alleles (FM) with more than 200 repeats. The 4th kind of allele is called "grey zone" or intermediate allele and contains in between 45 and 54 repeats and it has been proposed as a precursor for PM alleles.

The silencing of the FMR1 gene is the result of a series of intricate epigenetic modifications following the growth of the trinucleotide repeat [(15)]. The FM alleles undergo a methylation process in the CpG island within the gene promoter and in the CGG repeats [(16,17)]. In male patients with the FM allele, every cytosine within the CpG island is methylated, contrarily to healthy people who lack of any methylation [(18)]. A just recently found limit sequence in the FMR1 gene found 650 to 800 nucleotides upstream from the duplicated area that suffers methylation. This border sequence, because of its chromatin interaction, limits the hypermethylated area of the genome, protecting the promoter of FMR1 from possible methylation [(1617,19)]. In individuals with FXS the methylated limit sequence is lost allowing the expansion of the methylation approximately the promoter of the FMR1 gene. This finding highly recommend that changes in the series of nucleotides and conformational structure of the chromatin of the boundary sequences would prefer the epigenetic changes that would cause FMR1 silencing and eventually preventing FMRP production [(20)]. The Fragile X Syndrome is normally caused by the methylation and gene silencing associated with the full mutation although deletions of the coding area of the gene can also cause absence of FMRP. In addition, point mutations or reading frame shifts can also take place resulting in a practical deficit of the protein FMRP and the following phenotype; nevertheless, these genomic modifications account just for less than 1% of all FXS cases explained [(20)].



Figure 1: **The four alleles of the human *FMR1* gene [(6)].**

- ***Early diagnosis and screening for FXS alleles:***

The results of a pilot newborn screening (NBS) study for FXS in the United States, based on the screening of 11,217 newborns, indicated that the observed occurrence of a PM allele is 1:188 in women and 1:480 in males, while the occurrence of gray-zone alleles (45 - 54 CGG repeats) is 1:70 in females and 1:107 in males [(21)]. PM occurrence was discovered to be various in numerous ethnic groups; it was higher in individuals of blended European descent compared with that in African American and Hispanic individuals (for both males and females) and shows a greater incidence for PM compared with that in previous studies [(22,23)]. NBS for FMR1 mutations is not presently included in the NBS program, primarily since it might likewise determine FMR1 anomalies that may not develop a serious FXS due to partial inactivation (UFM) in addition to carriers that might establish FXTAS later in life. NBS has actually recently captured attention with the introduction of targeted treatments with encouraging results [(24,25)] and making use of brand-new PCR-based population screening techniques [(21,26)]. Of note, in a recent European research study of 213 FXS prenatal diagnoses, 17.6% of those with a family history of unidentified ID were discovered to be FXS carriers [(26)].

- ***Synaptic receptor dysfunction:***

FMRP is an RNA-binding protein, and, regardless of its clear shuttling from the nucleus to the cytoplasm [(27)], only the cytoplasmic function of FMRP has actually been well defined. FMRP forms big cytoplasmic ribonucleoparticles consisting of numerous other proteins [(28)] and RNAs [(28)]. FMRP has actually been discovered in P bodies and stress granules also, where it forms translationally quiet preinitiation complexes [(29)] (**Figure 2**). FMRP manages stability, subcellular transport, and translation of neuronal mRNAs encoding for proteins included the in synaptic structure and function [(29,30)]. High-throughput screenings supported by accompanying little scale studies have actually exposed that a broad variety of neuronal mRNAs, with a big percentage encoding for presynaptic and postsynaptic proteins, is deregulated in the lack of FMRP, recommending that concerted alteration of lots of proteins contributes to the FXS phenotype [(31)].



Figure 2: Effects of receptor signaling pathways on FMRP-mediated regulation at synapses. [(29)]

- ***Factors associated with FXS effecting the quality of life:***

Sleep disorder in FXS:

Sleep issues are observed in around 10% to 25% of normally establishing children and teenagers, [32] but the occurrence is considerably greater in children with ID and ASD, ranging from 36% to 73% [33,34,35]. There have actually been very few published studies recording the frequency and patterns of sleep issues in individuals with FXS [36,37]. A detailed analysis of 90 children with FXS, utilizing the standardized adult screen, the Children's Sleep Habits Questionnaire (CSHQ), and a 2-week diary to record sleep bothersome and routine locations [37], discovered that nearly half of children with FXS had scientifically considerable sleep issues, no matter whether they were getting medication to improve sleep. A second study [38] was a massive adult study of 1295 children with FXS where 32% were reported to have sleep troubles, consisting of problem dropping off to sleep and regular night awakenings. In the FXCRC Database, only 27% of parents of individuals with FXS reported sleep issues, with little distinction between male and female patients.

In the FXCRC population, the CSHQ was administered to a convenience subsample of 29 patients. The average CSHQ score was 46, which is comparable to the typical CSHQ rating [42] reported by Kronk et a [37] in 2009. In the original community sample that was used to develop the instrument [39], the average score (56.2) was higher, but these children were below the FXCRC subjects.

Among the Kronk studies [37,38] also reported that loud snoring and obstructive sleep apnea (OSA) happened in 38% and 34%, respectively, of children with FXS. Additionally, results from the FXCRC database showed a total lower frequency of OSA of 7% of patients. The general disparity in the occurrence between these research studies can most likely be credited to distinctions in study style, sample size, information collection protocols, and research study goals, but it appears that airway blockage is more typical in FXS than in the general population. The exact frequency of sleep issues in FXS is unclear, children with ID, in particular, require appropriate sleep for ideal neurobehavioral functioning. Monitoring and handling OSA and other sleep problems are of particular significance in FXS because of their relationship to decrements in daytime performance and increased behavioral issues [40].

Physiological markers of caregiver stress:

More just recently, psychological well-being result research study has actually been complemented with studies of physiological steps. An impaired hypothalamic-pituitary-adrenal (HPA) axis response and dysregulated cortisol patterns have actually been observed in spousal caregivers of patients with dementia [41] along with in moms of individuals with autism spectrum conditions (ASD) and fragile X syndrome (FXS) [42,43]. Caretakers of children with autism and attention deficit hyperactivity disorder (ADHD) likewise had greater concentrations of proinflammatory biomarkers than moms and dads of typically developing children [44].

Plasma norepinephrine levels of caregivers of patients with AD in action to a tension job were predicted by their depression symptoms, even when controlling for age, caretaker distress, presence of caretaker high blood pressure, and care recipient level of cognitive function [45]. On the other hand, personal proficiency (i.e., belief that a person can manage life's obstacles) was inversely associated with mean arterial pressure and systolic blood pressure worths [46]. The exact same group later discovered that high levels of depressive and stress and anxiety symptoms were connected with extended considerate activation in chronically stressed caregivers [47]. Chronic stress (at work or house) has been connected to higher risk of myocardial infarction in the general population, in a big case-control study in 52 nations [48]. Caretakers might also neglect their own health needs and postpone essential diagnostic or restorative procedures, even more compounding their morbidity. Senior family caregivers who experience stress have a 63% higher death risk than age-matched non-caregivers [49].

4. CONCLUSION

Fragile X syndrome (FXS) is the most frequent type of acquired intellectual special needs and is likewise linked to other neurologic and psychiatric conditions. While the molecular functions of FMRP are still being marked, FMRP is mainly developed to function in regulating mRNA metabolic process in brain. The wide variety of putative mRNA targets and several FMRP-interacting proteins with overlapping function might describe the large and variable physical phenotypes observed in FXS. FXS care needs substantial resources that are primarily non-medical in nature and are higher for children than for adults. Compared with associated diseases, FXS makes up an especially high problem for caretakers. Utilizing a bottom-up method and a wide variety of standardised measures, the outcomes of this study underscore the need for greater awareness of the burden of FXS along with an assessment of brand-new and existing interventions to resolve it.

REFERENCES

[1] Martyn M, Anderson V, Archibald A, et al. Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open. 2013;3(9):e003660pmid:24022395

[2] Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6(3-4):154–157.

[3] Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–914pmid:1710175

[4] Yu S, Pritchard M, Kremer E, et al. Fragile X genotype characterized by an unstable region of DNA. Science. 1991;252(5009):1179–1181pmid:2031189

[5] Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol. 2012;7:219–245.

[6] Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12):4314–4322.

[7] Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012;27(2):296–300.

[8] Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of Fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85:503–514.

[9] Payan C, Saldarriaga W, Isaza C, Alzate A. Estudio foco endémico de retardo mental en Ricaurte Valle. Acta Biológica Colombiana. 2001;6(2):88–88.

[10] Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):1–113.

[11] Hartley S. L., Seltzer M. M., Raspa M., Olmstead M., Bishop E. & Bailey D. B. (2011) Exploring the adult life of men and women with fragile X syndrome: results from a national survey. American Journal on Intellectual and Developmental Disabilities 116, 16–35. DOI: 10.1352/1944- 7558-116.1.16.

[12] Bailey D. B., Jr., Raspa M., Bishop E., Mitra D., Martin S., Wheeler A. et al. (2012) Health and economic consequences of fragile X syndrome for caregivers. Journal of Developmental and Behavioral Pediatrics 33, 705–12. DOI: 10.1097/DBP.0b013e318272dcbc.

[13] Verkerk AJ, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–914. doi: 10.1016/0092-8674(91)90397-H.

[14] Oberle I, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science. 1991;252(5009):1097–1102. doi: 10.1126/science.252.5009.1097.

[15] Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet. 2005;14(2):267–277.

[16] Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–822.

[17] Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W. A distinct DNA-methylation boundary in the 5'-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet. 2009;85(5):606–616.

[18] Stöger R, Kajimura TM, Brown WT, Laird CD. Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet. 1997;6(11):1791–1801.

[19] Malter HE, Iber JC, Willemsen R, de Graaff E, Tarleton JC, Leisti J, et al. Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet. 1997;15(2):165–169.

[20] Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1(6):397–400.

[21] Tassone F, et al. Newborn screening in fragile X syndrome: prevalence and allele distribution of the FMR1 gene. Paper presented at: American College of Medical Genetics Annual Clinical Genetics Meeting; July 26, 2012; Charlotte, North Carolina, USA. http://www.fragilex.org/community/international-fragile-x-conference/miami2012/agenda/ .

[22] Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11(4):324–329. doi: 10.2353/jmoldx.2009.080173.

[23] Dombrowski C, Levesque ML, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11(4):371–378. doi: 10.1093/hmg/11.4.371.

[24] Jacquemont S, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra61.

[25] Berry-Kravis E, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46(4):266–271. doi: 10.1136/jmg.2008.063701.

[26] Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10(1):43–49. doi: 10.2353/jmoldx.2008.070073.

[27] Eberhart DE, Malter HE, Feng Y, Warren ST. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996;5(8):1083–1091. doi: 10.1093/hmg/5.8.1083.

[28] Sittler A, Devys D, Weber C, Mandel JL. Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. Hum Mol Genet. 1996;5(1):95–102. doi: 10.1093/hmg/5.1.95.

[29] Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005;6(5):376–387.

[30] Brown V, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107(4):477–487.

[31] Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003;120(4):1005–1017. doi: 10.1016/S0306-4522(03)00406-8.

[32] Mindell JA, Meltzer LJ, Carskadon MA, Chervin RD. Developmental aspects of sleep hygiene: findings from the 2004 National Sleep Foundation Sleep in America Poll. Sleep Med. 2009;10(7):771–779. doi:710.1016/j.sleep.2008.1007.1016

[33] Richdale AL. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol. 1999;41(1):60–66pmid:10068053

[34] Robinson AM, Richdale AL. Sleep problems in children with an intellectual disability: parental perceptions of sleep problems, and views of treatment effectiveness. Child Care Health Dev. 2004;30(2):139–150pmid:14961866

[35] Polimeni MA, Richdale AL, Francis AJ. A survey of sleep problems in autism, Asperger's disorder and typically developing children. J Intellect Disabil Res. 2005;49(pt 4):260–268pmid:15816813

[36] Richdale AL. A descriptive analysis of sleep behaviour in children with fragile X. J Intellect Dev Disabil. 2003;28(2):135–144

[37] Kronk R, Dahl R, Noll R. Caregiver reports of sleep problems on a convenience sample of children with fragile X syndrome. Am J Intellect Dev Disabil. 2009;114(6):383–392. doi:310.1352/1944-7588-1114.1356.1383

[38] Kronk R, Bishop EE, Raspa M, Bickel JO, Mandel DA, Bailey DB Jr. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep. 2010;33(5):679–687pmid:20469810

[39] Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000;23(8):1043–1051pmid:11145319

[40] Goodlin-Jones B, Tang K, Liu J, Anders TF. Sleep problems, sleepiness and daytime behavior in preschool-age children. J Child Psychol Psychiatry. 2009;50(12):1532–1540pmid:19573036

[41] Jeckel CM, Lopes RP, Berleze MC, et al. Neuroendocrine and immunological correlates of chronic stress in 'strictly healthy' populations. Neuroimmunomodulation. 2010;17:9–18.

[42] Seltzer MM, Greenberg JS, Hong J, et al. Maternal cortisol levels and child behavior problems in families of adolescents and adults with ASD. J Autism Dev Disord. 2010;40:457–69.

[43] Seltzer MM, Barker ET, Greenberg JS, Hong J, Coe C, Almeida D. Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome. Health Psychol. 2012;31(5):612–22.

[44] Lovell B, Moss M, Wetherell M. The psychosocial, endocrine, and immune consequences of caring for a child with autism or ADHD. Psychoneuroendocrinology. 2012;37:534–42.

[45] Mausbach BT, Dimsdale JE, Ziegler MG, et al. Depressive symptoms predict norepinephrine response to a psychological stressor task in Alzheimer's caregivers. Psychosom Med. 2005;67:638–42.

[46] Harmell AL, Mausbach BT, Roepke SK, et al. The relationship between self-mastery and resting blood pressure in spousal Alzheimer's caregivers. Br J Health Psychol. 2011;16:317–28.

[47] Roepke SK, Chattillion EA, von Känel R, et al. Carotid plaque in Alzheimer caregivers and the role of sympathoadrenal arousal. Psychosom Med. 2011;73:206–13.

[48] Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:953–962.

[49] Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;282:2215–9.